Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics, Inc. (LENZ) Asset Writedowns and Impairment (2023)

LENZ Therapeutics (LENZ) has disclosed Asset Writedowns and Impairment for 1 consecutive years, with $13.3 million as the latest value for Q4 2023.

  • On a quarterly basis, Asset Writedowns and Impairment changed N/A to $13.3 million in Q4 2023 year-over-year; TTM through Dec 2023 was $20.6 million, a N/A change, with the full-year FY2023 number at $56.6 million, changed N/A from a year prior.
  • Asset Writedowns and Impairment was $13.3 million for Q4 2023 at LENZ Therapeutics, up from $7.2 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $13.3 million in Q4 2023 to a low of $7.2 million in Q3 2023.